Skip To Main Content

Áreas terapeúticas

Descubra la más reciente actualización sobre la evidencia científica y los datos basados en la vida real que se han recopilado en el campo de la epidemiología. Esta información incluye detalles sobre la carga que estas enfermedades imponen a las personas y a la sociedad en general, así como los métodos de control que se están implementando para hacer frente a estas situaciones.

También se aborda el impacto económico que tienen enfermedades como asma grave, cardiovascular, dermatitis atópica, diabetes o enfermedades raras, etc., en la vida de nuestra población. Estos elementos son fundamentales para comprender la magnitud del problema y para desarrollar estrategias efectivas que ayuden a mejorar la salud pública.

Ordenar por

Patología

Limpiar filtro
  • Filtros
Understanding the 556/146 Concept: Insights from Leading Experts

Understanding the 556/146 Concept: Insights from Leading Experts

556/146 for Lipid Management after ACS

556/146 for Lipid Management after ACS

556/146 for Lipid Management after ACS

556/146 for Lipid Management after ACS

556/146 for Lipid Management after ACS

556/146 for Lipid Management after ACS

556/146 for Lipid Management after ACS

556/146 for Lipid Management after ACS

Why Praluent is the Optimal Choice for Post-ACS Patients?

Why Praluent is the Optimal Choice for Post-ACS Patients?

Explore the compelling reasons why Praluent should be your first choice for patients with recent acute coronary syndrome who need to achieve their LDL-C goals. This informative video provides in-depth clinical insights and evidence, detailing how Praluent’s unique mechanism of action and proven efficacy can significantly improve patient outcomes. The video also covers tips on the 3 main factors: efficacy, safety, and administration to help you to integrate Praluent into your treatment plans. Enhance patient outcomes and elevate your practice with Praluent.

Why Praluent is the Optimal Choice for Post-ACS Patients?

Why Praluent is the Optimal Choice for Post-ACS Patients?

Explore the compelling reasons why Praluent should be your first choice for patients with recent acute coronary syndrome who need to achieve their LDL-C goals. This informative video provides in-depth clinical insights and evidence, detailing how Praluent’s unique mechanism of action and proven efficacy can significantly improve patient outcomes. The video also covers tips on the 3 main factors: efficacy, safety, and administration to help you to integrate Praluent into your treatment plans. Enhance patient outcomes and elevate your practice with Praluent.

Why Praluent is the Optimal Choice for Post-ACS Patients?

Why Praluent is the Optimal Choice for Post-ACS Patients?

Explore the compelling reasons why Praluent should be your first choice for patients with recent acute coronary syndrome who need to achieve their LDL-C goals. This informative video provides in-depth clinical insights and evidence, detailing how Praluent’s unique mechanism of action and proven efficacy can significantly improve patient outcomes. The video also covers tips on the 3 main factors: efficacy, safety, and administration to help you to integrate Praluent into your treatment plans. Enhance patient outcomes and elevate your practice with Praluent.

Why Praluent is the Optimal Choice for Post-ACS Patients?

Why Praluent is the Optimal Choice for Post-ACS Patients?

Explore the compelling reasons why Praluent should be your first choice for patients with recent acute coronary syndrome who need to achieve their LDL-C goals. This informative video provides in-depth clinical insights and evidence, detailing how Praluent’s unique mechanism of action and proven efficacy can significantly improve patient outcomes. The video also covers tips on the 3 main factors: efficacy, safety, and administration to help you to integrate Praluent into your treatment plans. Enhance patient outcomes and elevate your practice with Praluent.

Diabetes in Asians: Tailoring Management to Unique Metabolic Profiles

Diabetes in Asians: Tailoring Management to Unique Metabolic Profiles

Protecting the Future: Italy’s National Screening Law for Type 1 Diabetes 

Protecting the Future: Italy’s National Screening Law for Type 1 Diabetes 

Professor Emanuele Bosi discusses a mandatory screening program for Type 1 diabetes and celiac disease in children and adolescents, launched in Italy in 2024.

Diabetes in Asians: Tailoring Management to Unique Metabolic Profiles

Diabetes in Asians: Tailoring Management to Unique Metabolic Profiles

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

 

MAT-CO-2400825 V1.0 03/2024